William Blair downgraded Jasper Therapeutics (JSPR) to Market Perform from Outperform after the company reported updated data from the BEACON study and preliminary data from the open-label extension of briquilimab in chronic spontaneous urticaria. Jasper also disclosed that some of the multi-dose cohorts from BEACON were impacted by an inactive drug product lot and that development of briquilimab in asthma has been halted because the same inactive drug product lot was used for all patients in the ETESIAN asthma challenge study, the analyst noted. The firm is downgrading shares as a result of this “setback,” citing a lack of clarity around both the funding overhang and concerns related to drug product manufacturing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Buy Rating Affirmed for Jasper Therapeutics Amid Promising Efficacy and Resolved Trial Setbacks
- Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
- Jasper Therapeutics Reports Promising Briquilimab Study Results
- Jasper Therapeutics to stop ETESIAN study due to drug product lot issue
- Jasper Therapeutics reports updated data from BEACON study